Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Shionogi Eyes EUA of COVID Pill in South Korea via Sublicense to Local Firm
Shionogi said on September 16 that its group company has signed a sublicense deal with South Korea’s Ildong Pharmaceutical to pursue an emergency use authorization (EUA) for its COVID-19 pill ensitrelvir in the country and to subsequently negotiate for government…
To read the full story
BUSINESS
- Moderna’s mNEXSPIKE Grabs Japan Approval for XFG Variant
August 20, 2026
- Nipro’s Forxiga AG to Hit Shelves on September 4
August 20, 2026
- Teijin Taps CAR-T Expert Campana as Technical Advisor
August 20, 2026
- Sandoz Gets Broader Label for Genotropin Biosimilar
August 20, 2026
- Mochida to Take Over Topiloric from Fuji Yakuhin in October
August 20, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…